At a scientific symposium in San Francisco last month, some of the country’s foremost experts on lupus shared their insights about the current state of lupus clinical trial design. Read more.
Lupus Foundation of America supported study demonstrates that blocking STAT5 reduces the production of CD154 by half.
Adolescent-onset lupus has worse prognosis and increased risk of lupus-related kidney disease and death.
Study funded by the Foundation's National Lupus Research Program secures NIH planning grant to develop a multi-center trial of mesenchymal stem cells.
Flare rates among participants receiving a low dose of the b-cell blocker did not meet primary endpoint but were lower for individuals receiving a higher dose.
An international group of lupus experts has developed a set of recommendations to implement the treat-to-target strategy for managing lupus.
Lupus Foundation of America supported study finds combination therapy that includes hydroxychloroquine may be beneficial to pregnant patients with lupus and/or antiphospholipid syndrome.
New Tool Helps to Ensure Better Representation of Minorities in Future Lupus Quality of Life Studies
Researchers now have a cost effective tool to help them better understand the burden of disease among populations at high risk for developing lupus. Learn more.